Recent 8-K filings for OPK
Highest-materiality recent filing
OPKO Q3 net income $21.6M; Regeneron collaboration with $1B+ potential; sells BioReference oncology to Labcorp for $225M
- Q3 consolidated revenues $151.7M, down 12.6% YoY; operating income $48.1M vs $14.2M; diluted EPS $0.03 flat.
- Entered multi-program Regeneron collaboration for multispecific antibodies; upfront plus milestones >$200M per program, total potential >$1B.
-
OPKO Health Q1 revenue falls to $124.2M, net loss narrows; pipeline advances
Consolidated revenue $124.2M vs $149.9M YoY; net loss $54.8M ($0.07/sh) from $67.6M ($0.10/sh).
-
OPKO Health Q4 revenue $148.5M, net loss $31.3M; Regeneron deal >$1B
Q4 revenue $148.5M (down 19% YoY); net loss $31.3M ($0.04/share) vs $14.0M income in Q4 2024.
-
Q3 consolidated revenues $151.7M, down 12.6% YoY; operating income $48.1M vs $14.2M; diluted EPS $0.03 flat.
-
OPKO completes sale of BioReference oncology assets to Labcorp for $192.5M cash plus earnout
Transaction closed Sept 15, 2025; Labcorp paid $192.5M at closing, with up to $32.5M earnout.
-
OPKO Health Q2 revenue $156.8M down 14% YoY; net loss includes $91.7M convertible note charge
Consolidated revenue $156.8M vs $182.2M in Q2 2024; net loss $148.4M ($0.19/share) vs $10.3M loss ($0.01) prior year, including $91.7M non-recurring convertible note expense.
-
OPKO Health grants stock options and bonuses to CEO Frost and other executives
Compensation Committee granted stock options for 500,000 shares to CEO Phillip Frost, each at $1.31 exercise price.
-
Revenue $149.9M vs $173.7M YoY; net loss $0.10 per share vs $0.12 per share.
-
OPKO Health exchanges $159.2M convertible notes for 121.4M shares and $63.5M cash
Exchanged $152.5M (Mar 27) plus $6.75M (Mar 28) of 3.75% Convertible Senior Notes due 2029.
-
OPKO Health to exchange $152.5M convertible notes for 116.7M shares and ~$60.1M cash
Exchange of $152,471,000 principal of 3.75% Convertible Senior Notes due 2029 for 116,706,310 common shares and ~$60.1M cash, including accrued interest.
-
OPKO Health to sell oncology testing assets to Labcorp for up to $225M
Purchase price: $192.5M at closing plus up to $32.5M in earnout based on performance.
-
OPKO Health reports Q4 net income of $14M, revenue $183.6M; BARDA/Merck milestones boost pharma
Consolidated Q4 revenue $183.6M vs $181.9M; net income $14.0M ($0.01 diluted EPS) vs net loss of $66.5M in Q4 2023.
-
OPKO reports Q3 net income $24.9M; sells BioReference assets for $237.5M, authorizes $100M buyback
Q3 revenue $173.6M vs $178.6M YoY; net income $24.9M ($0.03/diluted) vs net loss $84.5M ($0.11) in 2023.
-
OPKO Health closes $237.5M sale of BioReference clinical diagnostics assets to Labcorp
Labcorp acquired select BioReference diagnostics assets outside NY/NJ for $237.5M cash.
-
OPKO reports Q2 net loss $10.3M; enters $250M note deal, plans $100M buyback
Q2 total revenues $182.2M (down from $265.4M YoY); operating loss $61.7M vs income $7.0M; net loss $0.01/share.
-
Notes bear interest at 3-month SOFR + 7.5% (floor 4%); interest-only for first 4 years.
-
OPKO Health to sell BioReference assets to Labcorp for $237.5M; Q1 net loss $81.8M
Agreed to sell select BioReference Health assets to Labcorp for $237.5M; assets generate ~$100M annual revenue; closing expected H2 2024.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.70 · Most common event earnings